Treatment of Hypertrophic Cardiomyopathy

Nowadays people believe that hypertrophic cardiomyopathy (HCM) is predominantly a genetically determined disease of the heart muscle, characterized by a relentlessly progressive course with a high risk of life-threatening arrhythmias and sudden cardiac death (SCD). Many people are unaware that HCM is currently the most common form of cardiomyopathy. Statistics indicate that 300,000 people in Russia suffer from this condition. HCM accounts for 36% of sudden cardiac deaths, and this is often how the disease debuts. There are other genetic and non-genetic diseases that can mask HCM. HCM is characterized by massive (more than 15 mm) hypertrophy of the myocardium of the left and/or, in rare cases, the right ventricle, often of an asymmetrical nature, with frequent development of left ventricular outflow tract obstruction in the absence of known causes (such as arterial hypertension, heart defects, and specific heart diseases). The choice of treatment tactics mainly depends on the peculiarities of the disease course, the patient's age, and when the disease was detected.